Equipoise review

Blinding : the process of preventing one or more of patients, clinicians, investigators, and data analysts from knowing whether individual patients are receiving the investigational intervention(s) or the control (or standard) intervention(s) in a clinical trial. (Also known as masking.) Blinding is intended to eliminate the possibility that knowledge of which intervention is being received will affect patient outcomes, investigator behaviors that may affect outcomes, or assessment of outcomes. Blinding is not always practical (. when comparing surgery to drug treatment), but it should be used whenever it is possible and compatible with optimal patient care. The terms “single-blinded,” “double-blinded,” and “triple-blinded” refer to which parties are blinded, ., one or more of patients, investigators, and data analysts; however, these terms are used inconsistently and the specific parties who are blinded in a trial should be identified.

Equipoise is not an ideal steroid for the drug tested athlete however. This drug has the tendency to produce detectable metabolites in the urine months after use, a worry most commonly associated with Deca-Durabolin. This is of course due to the high oil solubility of long chain esterified injectable steroids, a property which enables the drug to remain deposited in fatty tissues for extended periods of time. While this will reliably slow the release of steroid into the blood stream, it also allows small residual amounts to remain present in the body far after the initial injection. The release of stubborn stores of hormone would no doubt also be enhanced around contest time, a period when the athlete drastically attempts to mobilize unwanted body fat. If enough were used in the off-season, the athlete may actually fail a drug screen for boldenone although many months may have past since the drug was last injected.

Equipoise review

equipoise review


equipoise reviewequipoise reviewequipoise reviewequipoise reviewequipoise review